Stereotactic body radiotherapy: An emerging treatment approach for localized prostate cancer

Technology in Cancer Research and Treatment

Volumn 8, Issue 5, 2009, Pages 387-392

  Friedland, Jay L ^a   Freeman, Debra E ^a   Masterson McGary, Mary Ellen ^b   Spellberg, David M ^c  

^a Naples Radiation Oncology   (United States)

^b Crisis Center of Tampa Bay   (United States)

^c Naples Urology Associates   (United States)

Author keywords

Brachytherapy; Hypofractionation; Prostate cancer; Stereotactic radiotherapy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RADIATION DOSE; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT OUTCOME; TUMOR BIOPSY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; COHORT STUDIES; DOSE FRACTIONATION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATIC NEOPLASMS; RADIOSURGERY;

EID: 70349308343     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460900800509     Document Type: Article

References (20)

1. Hanks, G. E., Hanlon, A. L., Epstein, B., Horwitz, E. M. Dose response in prostate cancer with 8-12 years' follow-up. Int J Radiat Oncol Biol Phys 54(2), 427-435. (2002). (Pubitemid 35286808)
2. Zelefsky, M. J., Fuks, Z., Hunt, M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 1 , 876-881 (2001) (Pubitemid 32750970)
3. Zietman, A. L., DeSilvio, M. L., Slater, J. D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. Jama 294(10),1233-1239 (2005).
4. Fowler, J., Chappell, R., Ritter, M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50(4), 1021-1031 (2001). (Pubitemid 32594841)
5. Fowler, J. F. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 44(3), 265-276 (2005).
6. Wang, J. Z., Guerrero, M., Li, X. A. How low is the alpha/beta ratio for prostate cancer? Int J Radiat Oncol Biol Phys 55(1),194-203 (2003). (Pubitemid 36020360)
7. Mate, T. P., Gottesman, J. E., Hatton, J., Gribble, M., Van Hollebeke, L. High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report. Int J Radiat Oncol Biol Phys 41(3), 525-533 (1998). (Pubitemid 28275080)
8. Demanes, D. J., Rodriguez, R. R., Schour, L., Brandt, D., Altieri, G. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 61(5),1306-1316 (2005). (Pubitemid 40470411)
9. Martinez, A. A., Pataki, I., Edmundson, G., Sebastian, E., Brabbins, D., Gustafson, G. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys 49(1), 61-69 (2001). (Pubitemid 32041277)
10. Demanes, D., Altieri, G., Barnaba, M., Brandt, D., Hill, D., Schour, L. High dose rate (HDR) monotherapy is equivalent to combined HDR brachytherapy and external beam radiation therapy (EBRT) for early prostate cancer. Int J Radiat Oncol Biol Phys 66(3), S351 (2006).
11. Grills, I. S., Martinez, A. A., Hollander, M., et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 171(3), 1098-1104 (2004). (Pubitemid 38327535)
12. Madsen, B. L., his, R. A., Pham, H. T., Fowler, J. F., Esagui, L., Corman, J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 67(4),1099-1105 (2007).
13. King, C. R., Brooks, J. D., Gill, H., Pawlicki, T., Cotrutz, C., Presti, J. C., Jr. Stereotactic Body Radiotherapy for Localized Prostate Cancer: Interim Results of a Prospective Phase II Clinical Trial. Int J Radiat Oncol Biol Phys 73(4), 1043-1048 (2009)
14. Hara, W., Patel, D., Pawlicki, T., Cotrutz, C., Presti, J., King, C. Hypofractionated stereotactic radiotherapy for prostate cancer: early results. Int J Radiat Oncol Biol Phys 66(3), S324-S325 (2006).
15. Fuller, D. B., Naitoh, J., Lee, C., Hardy, S., Jin, H. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys 70(5),1588-1597 (2008).
16. Rosen, R. C., Cappelleri, J. C., Gendrano, N., 3rd. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res 14(4), 226-244 (2002).
17. Potosky, A. L., Davis, W. W., Hoffman, R. M., et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 96(18),1358-1367 (2004).
18. Sanda, M. G., Dunn, R. L., Michalski, J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358(12),1250-1261 (2008).
19. Schour, L., Demanes, D. J., Altieri, G. A., Brandt, D., Barnaba, M., Skoolisariyaporn, P. High Dose Rate Monotherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 63, S315 (2005).
20. ASTRO Emerging Technology Committee. Stereotactic Body Radiotherapy (SBRT) For Primary Management of Early-Stage, Low-Intermediate Risk ProstateCancer. [http://www.astro.org/HealthPolicy/EmergingTechnology/ EvaluationProjects/documents/SBRTpros.pdf].